Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors (Q36470125)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors |
scientific article |
Statements
1 reference
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors (English)
1 reference
Narikazu Boku
1 reference
Toshiaki Takahashi
1 reference
Haruyasu Murakami
1 reference
Tateaki Naito
1 reference
Asuka Tsuya
1 reference
Yukiko Nakamura
1 reference
Akira Ono
1 reference
Nozomu Machida
1 reference
Kentaro Yamazaki
1 reference
Keiji Imai
1 reference
Emiko Ohki
1 reference
Nobuyuki Yamamoto
1 reference
1 reference
Identifiers
1 reference